 | This article needs additional citations for verification. (August 2022) |
| Combination of | |
|---|---|
| Flupentixol | Typical antipsychotic |
| Melitracen | Tricyclic antidepressant |
| Clinical data | |
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| (verify) | |
Flupentixol/melitracen (trade name Frenxit, Franxit, Placida, Deanxit, Anxidreg, Danxipress, Mocalm) is a combination of two psychoactive agents flupentixol and melitracen. It is designed for short term usage only. It is produced by Lundbeck.[1]
Flupentixol is a thiazolyl (thioanthracene) antipsychotic, and melitracen is a tricyclic antidepressant. Low dose Flupentixol (0.5mg-3mg) has antidepressant and anti-anxiety effects, while melitracen has antidepressant effect. The mixture of the two components is used to treat mild to moderate mental disorders.
Flupentixol acts as a dopamine 1 and 2 receptor antagonist and melitracen acts in similar way to other tricyclic antidepressants blocking the reuptake of serotonin and norepinephrine in presynaptic terminals.
- ^ Sweetman SC, ed. (2009). "Preparations". Martindale: The complete drug reference (36th ed.). London: Pharmaceutical Press. p. 2607. ISBN 978-0-85369-840-1.